ストックスクリーナーアプリを入手
770.63
6.03%
-50.83
前日終値:
$821.46
開ける：
$816.89
24時間の取引高:
3.38M
Relative Volume:
0.92
時価総額：
$737.81B
収益：
$49.00B
当期純損益:
$11.11B
株価収益率:
62.70
EPS:
12.29
ネットキャッシュフロー:
$-1.27B
1週間 パフォーマンス:
-12.80%
1か月 パフォーマンス:
+4.57%
6か月 パフォーマンス:
-0.57%
1年 パフォーマンス:
+0.68%
1日の値動き範囲:
$771.00
$818.42
1週間の範囲:
$771.57
$902.50
52週間の値動き範囲:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
LLY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
771.00 | 737.81B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.07 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.12 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
66.07 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.87 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly (LLY) Raises Dividend by 15%, Maintains Shareholder Payout for 55th Consecutive Year - TipRanks
Eli Lilly Stock Plunges: LLY Shares Dive Nearly 3% in Morning Trading - paginasiete.bo
Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip? - The Motley Fool
Eli Lilly (LLY) Partners with Alchemab on ALS Drug Development - GuruFocus
Lilly to Break Ground on $4.5 Billion Medicine Foundry in Lebanon - WIBC
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April - The Motley Fool
Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company - PrimePublishers.com
Lilly to break ground on $4.5 billion medicine foundry in Lebanon - WISH-TV
Eli Lilly (LLY) Maintains Quarterly Dividend at $1.50 Per Share - GuruFocus
Eli Lilly announces $1.50 Q2 dividend per share By Investing.com - Investing.com India
Eli Lilly announces $1.50 Q2 dividend per share - Investing.com
Lilly declares second-quarter 2025 dividend - Quantisnow
LLY stock news: Eli Lilly Declares $1.50 Quarterly Dividend - paginasiete.bo
Lilly declares second-quarter 2025 dividend | Eli Lilly and Company - Eli Lilly and Company
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.7% Yield - StreetInsider
Eli Lilly Sets $1.50 Per Share Dividend Payout: Key Dates and Details for Q2 2025 - Stock Titan
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know - Yahoo Finance
Eli Lilly’s Strategic Adjustments and Growth Prospects Reinforce Buy Rating Despite Setbacks - TipRanks
Eli Lilly First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo
This pill could forever change how people lose weight3 May 2025Time Magazine EuropeReadly | All magazines - Readly | All magazines - one magazine app subscription
Eli Lilly and Company (NYSE:LLY) Q1 2025 Earnings Call Transcript - Insider Monkey
Eli Lilly (LLY) Stock Rating Maintained by UBS Despite Price Tar - GuruFocus
Eli Lilly (NYSE:LLY) Announces Promising Trial Data And Updates 2025 Guidance - Yahoo Finance
UBS cuts Eli Lilly stock target to $1,050, maintains Buy rating - Investing.com UK
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - AOL.com
Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why. - MSN
Cantor Fitzgerald maintains $975 target on Eli Lilly stock By Investing.com - Investing.com India
Cantor Fitzgerald maintains $975 target on Eli Lilly stock - Investing.com
Eli Lilly Stays Strong Despite CVS Dropping Key Drug - Finimize
Leerink sees Eli Lilly stock dip as buying chance, keeps $944 target - Investing.com India
Eli Lilly stock sell-off was 'overreaction': Analysts - Yahoo Finance
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - AOL.com
Lilly to participate in Bank of America Securities 2025 Healthcare Conference - Quantisnow
Eli Lilly CFO to Share Strategic Insights at Major Bank of America Healthcare Conference - Stock Titan
Positive Outlook for Eli Lilly & Co. Despite Competitive Challenges - TipRanks
Eli Lilly (LLY) Price Target Reduced by UBS Analyst Despite Stro - GuruFocus
Eli Lilly (LLY) sell-off 'overdone' on CVS move on WegovyLeerink - StreetInsider
Eli Lilly Tackles CVS Health's Cut In Zepbound Coverage - Finimize
Street View: Eli Lilly well positioned in weight-loss market despite CVS's decision - TradingView
Eli Lilly selloff on CVS Wegovy news overdone, says JPMorgan - TipRanks
Eli Lilly & Co: Strong Market Position and Growth Potential Amid Competitive Pressures - TipRanks
Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight - GuruFocus
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Innovations - GuruFocus
Eli Lilly (LLY) Faces Market Cap Drop Amid Competitive Pressure - GuruFocus
Eli Lilly (LLY) Prepares for Potential Tariffs on Pharmaceuticals - GuruFocus
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal - MSN
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge - Reuters
Friday Five – Pharma's tariff-proofing playbook, Novo slims Lilly's lead, vaccine policy shakeup…and more - FirstWord Pharma
Obesity Drug Price Wars Heating Up as CVS Picks Novo Over Lilly - Bloomberg.com
Lilly Cuts Earnings Guidance on Research Charges, Shares Fall - Bloomberg.com
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
0.20%
大文字化:
|
ボリューム (24 時間):